Work bench vice

A work bench comprises vice means having three vice plates 6 for gripping an object in the vice means and wherein the vice plates can be independently moved to contact the object. The vice plates are actuable to operate in a common plane, with one being optionally pivotal to act in a plane at an angle. e.g. orthogonal, thereto. ...

HUMAN-LIKE HEAVY CHAIN ANTIBODY VARIABLE DOMAIN (VHH) DISPLAY LIBRARIES

Heavy chain antibody variable domain (VHH) display libraries are described comprising human-like VHH comprising three synthetically generated complementarity determining region (CDR) areas in which the amino acids at each of positions 44 and 45 or positions 37, 44, 45, and 47 comprise the amino acid at the corresponding position of a Camelid VHH, wherein the amino acid positions are according to Kabat numbering Human-like VHHs identified using these libraries may be useful for the manufacture of therapeutics for treating diseases and disorders.

HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Capacitor structure and method of manufacturing the same

Provided is a capacitor structure including a substrate, a cup-shaped lower electrode, a top supporting layer, a capacitor dielectric layer, and an upper electrode. The cup-shaped lower electrode is located on the substrate. The top supporting layer surrounds the upper portion of the cup-shaped lower electrode. The top supporting layer includes a high-k material. Surfaces of the cup-shaped lower electrode and the top supporting layer are covered by the capacitor dielectric layer. A surface of the capacitor dielectric layer is covered by the upper electrode.

FULL-LENGTH HUMAN IMMUNOGLOBULIN G ANTIBODY LIBRARIES FOR SURFACE DISPLAY AND SECRETION IN SACCHAROMYCES CEREVISIAE

A Saccharomyces cerevisiae antibody display system that simultaneously secrets and displays antibody fragments from a very large size synthetic nave human antibody library for therapeutic antibody lead discovery and engineering is described. A bait anchor complexed with a monovalent antibody fragment is tethered on the surface of the S. cerevisiae host cell, wherein the fragment can be assayed for antigen binding, while the full bivalent antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies from the library that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells used for making the antibody display system are also provided along with methods of use thereof.

CAPACITOR STRUCTURE

Provided is a capacitor structure including a substrate, a cup-shaped lower electrode, a top supporting layer, a capacitor dielectric layer, and an upper electrode. The cup-shaped lower electrode is located on the substrate. The top supporting layer surrounds the upper portion of the cup-shaped lower electrode. The top supporting layer includes a high-k material. 1. A capacitor structure , comprising:a cup-shaped lower electrode located on a substrate;a top supporting layer surrounding an upper portion of the cup-shaped lower electrode, wherein the top supporting layer comprises a high-k material;a capacitor dielectric layer covering a surface of the cup-shaped lower electrode and a surface of the top supporting layer; andan upper electrode covering a surface of the capacitor dielectric layer.2. The capacitor structure of claim 1 , wherein the top supporting layer conformally covers and is connected to upper sidewalls of two adjacent cup-shaped lower electrodes to form a U-shaped structure claim 1 , and the top supporting layer is a portion of the capacitor dielectric layer.3. The capacitor structure of claim 1 , further comprising a bottom supporting layer surrounding a lower portion of the cup-shaped lower electrode claim 1 , wherein a gap exists between the bottom supporting layer and the top supporting layer claim 1 , and the gap is filled with air.4. The capacitor structure of claim 1 , wherein the top supporting layer comprises zirconium oxide (ZrO) claim 1 , lanthanum oxide (LaO) claim 1 , yttrium oxide (YO) claim 1 , gadolinium oxide (GdO) claim 1 , or a combination thereof.5. The capacitor structure of claim 1 , wherein a top surface of the top supporting layer and a top surface of the cup-shaped lower electrode are coplanar.6. The capacitor structure of claim 1 , wherein heights of two sidewalls of the cup-shaped lower electrode are the same. This application is a divisional application of and claims the priority benefit of U.S. application Ser. No. 15/986 ...

CAPACITOR STRUCTURE AND METHOD OF MANUFACTURING THE SAME

Provided is a capacitor structure including a substrate, a cup-shaped lower electrode, a top supporting layer, a capacitor dielectric layer, and an upper electrode. The cup-shaped lower electrode is located on the substrate. The top supporting layer surrounds the upper portion of the cup-shaped lower electrode. The top supporting layer includes a high-k material. Surfaces of the cup-shaped lower electrode and the top supporting layer are covered by the capacitor dielectric layer. A surface of the capacitor dielectric layer is covered by the upper electrode. 1. A capacitor structure , comprising:a cup-shaped lower electrode located on a substrate;a top supporting layer surrounding an upper portion of the cup-shaped lower electrode, wherein the top supporting layer comprises a high-k material;a capacitor dielectric layer covering a surface of the cup-shaped lower electrode and a surface of the top supporting layer; andan upper electrode covering a surface of the capacitor dielectric layer.2. The capacitor structure of claim 1 , wherein the top supporting layer conformally covers and is connected to upper sidewalls of two adjacent cup-shaped lower electrodes to form a U-shaped structure claim 1 , and the top supporting layer is a portion of the capacitor dielectric layer.3. The capacitor structure of claim 1 , further comprising a bottom supporting layer surrounding a lower portion of the cup-shaped lower electrode claim 1 , wherein a gap exists between the bottom supporting layer and the top supporting layer claim 1 , and the gap is filled with air.4. The capacitor structure of claim 1 , wherein the top supporting layer comprises zirconium oxide (ZrO) claim 1 , lanthanum oxide (LaO) claim 1 , yttrium oxide (YO) claim 1 , gadolinium oxide (GdO) claim 1 , or a combination thereof.5. The capacitor structure of claim 1 , wherein a top surface of the top supporting layer and a top surface of the cup-shaped lower electrode are coplanar.6. The capacitor structure of claim 1 ...

Method of manufacturing memory device

A method of manufacturing a memory device includes following steps. A first dielectric layer is formed on the substrate between bit-line structures. First trenches are formed in the first dielectric layer. A second dielectric layer is formed to fill in the first trenches. A portion of the first dielectric layer is removed, so that a top surface of the first dielectric layer is lower than a top surface of the second dielectric layer. A first mask layer is formed to cover the top surfaces of the first and second dielectric layers. A first etching process is performed to form second trenches in the first dielectric layer. A third dielectric layer is formed to fill the second trenches. The first dielectric layer is removed to form contact openings between the second and third dielectric layers. A conductive material is formed to fill in the contact openings.

CAPACITOR AND MANUFACTURING METHOD THEREOF

A capacitor and a manufacturing method thereof are provided. The capacitor includes a cup-shaped lower electrode, a capacitive dielectric layer, an upper electrode, and a support layer. The support layer includes an upper support layer surrounding an upper portion of the cup-shaped lower electrode, a middle support layer surrounding a middle portion of the cup-shaped lower electrode, and a lower support layer surrounding a lower portion of the cup-shaped lower electrode. Surfaces of the upper support layer, the middle support layer, and the lower support layer are covered by the capacitive dielectric layer.

FUNCTIONAL CELL SURFACE DISPLAY OF LIGANDS FOR THE INSULIN AND/OR INSULIN GROWTH FACTOR 1 RECEPTOR AND APPLICATIONS THEREOF

Systems for making, identifying, and selecting recombinant cells that express a ligand for the insulin receptor (IR) or insulin growth factor I (IGF-1) receptor are described. In general, libraries of recombinant cells are constructed that are capable of displaying a plurality of ligand molecules on the cell surface. Recombinant cells that display a ligand in a form accessible for binding to the IR and/or IGF-1 receptor can be detected and the recombinant cells displaying said ligands can be selected and isolated using cell sorting technologies. In particular aspects, the system is useful for constructing and screening libraries of recombinant cells that express and displaying insulin analogue precursors molecules to identify and select recombinant cells in the library that bind the IR and/or IGF-1 receptor with a desired affinity and/or avidity. 1. A method for detecting and isolating recombinant cells that express a ligand for the insulin receptor (IR) or insulin growth factor 1 (IGF-1) receptor , comprising:(a) constructing recombinant cells wherein each recombinant cell transiently or stably expresses a fusion protein comprising a polypeptide, wherein the fusion protein is secreted and capable of being displayed on the surface of the recombinant cell, by transforming host cells with nucleic acid molecules encoding the fusion protein;(b) detecting recombinant cells that display on the cell surface thereof a fusion protein comprising a polypeptide capable of binding the IR or IGF-1 receptor by contacting the recombinant cells produced in (a) with the IR or IGF-1 receptor; and(c) isolating the recombinant cells that display the fusion protein detected in step (b) to provide the recombinant cells that express the ligand for the IR or IGF-1 receptor.2. The method of claim 1 , wherein the polypeptide is fused to a cell surface anchoring moiety or protein or cell surface binding portion thereof.3. The method of claim 2 , wherein the cell surface anchoring protein is ...

CHIP BONDING PROCESS

A chip bonding process includes the following steps. At least one chip is transferred onto a carrier, and a negative pressure environment is provided. Heat is provided to the at least one chip and/or the carrier, and a positive pressure is applied onto the at least one chip.

HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Generative Modeling Leveraging Deep Learning for Antibody Affinity Tuning

A computer-implemented method is disclosed for candidate antibody exploration. The method includes receiving sequence reads from a sequencing system, wherein each sequence read comprises a target gene for expressing a candidate antibody, wherein each sequence read is associated with a binding affinity to a target antigen. The method includes generating a sequence representation for each sequence read, representing the amino acid sequences of the sequence read. The method includes training a binding affinity prediction model with the sequence representations and the binding affinities. The method includes generating a synthetic candidate sequence read that is different from the sequence reads. The method includes generating a sequence representation for the synthetic candidate sequence read. The method includes determining a binging affinity prediction for the synthetic candidate sequence read by applying the binding affinity prediction model to the sequence representation for the synthetic candidate sequence read.

Capacitor and manufacturing method thereof

A capacitor and a manufacturing method thereof are provided. The capacitor includes a cup-shaped lower electrode, a capacitive dielectric layer, an upper electrode, and a support layer. The support layer includes an upper support layer surrounding an upper portion of the cup-shaped lower electrode, a middle support layer surrounding a middle portion of the cup-shaped lower electrode, and a lower support layer surrounding a lower portion of the cup-shaped lower electrode. Surfaces of the upper support layer, the middle support layer, and the lower support layer are covered by the capacitive dielectric layer.

AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF

Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

High affinity antibodies targeting tau phosphorylated at serine 413

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

PROMOTERS FOR HIGH LEVEL RECOMBINANT EXPRESSION IN FUNGAL HOST CELLS

The present invention provides, in part, promoters for recombinant expression of polypeptides in host cells such as as well as methods of use thereof. 1. An isolated hybrid polynucleotide comprising a promoter selected from the group consisting of:{'i': 'Pichia pastoris', 'GAPDH promoter;'}{'i': 'Pichia pastoris', 'Pp02g05010 (PpPIR1) promoter;'}{'i': 'Pichia pastoris', 'Pp05g08520 (ScCCW12) promoter;'}{'i': 'Pichia pastoris', 'Pp01g10900 (ScCHT2) promoter;'}{'i': 'Pichia pastoris', 'Pp05g07900 (ScAAC2/PET9) promoter;'}{'i': 'Pichia pastoris', 'Pp02g01530 (ScPST1) promoter;'}{'i': 'Pichia pastoris', 'Pp05g00700 promoter;'}{'i': 'Pichia pastoris', 'Pp02g04110 (ScPOR1) promoter;'}{'i': 'Pichia pastoris', 'Pp01g03600 (ScBGL2) promoter;'}{'i': 'Pichia pastoris', 'Pp01g14410 (ScACO1) promoter;'}{'i': 'Pichia pastoris', 'Pp01g09650 (ScYHR021C) promoter;'}{'i': 'Pichia pastoris', 'Pp01g02780 (ScYLR388W) promoter;'}{'i': 'Pichia pastoris', 'Pp03g09940 (ScPIL1) promoter;'}{'i': 'Pichia pastoris', 'Pp02g10710 (ScMDH1) promoter;'}{'i': 'Pichia pastoris', 'Pp01g09290 (ScFBA1) promoter;'}{'i': 'Pichia pastoris', 'Pp03g03520 (PpDAS2) promoter;'}{'i': 'Pichia pastoris', 'Pp03g08760 (ScCWP1) promoter;'}{'i': 'Pichia pastoris', 'Pp03g00990 (ScYGR201c) promoter;'}{'i': 'Pichia pastoris', 'Pp02g05270 (AN2948.2) promoter;'}{'i': 'Pichia pastoris', 'Pp02g12310 (ScDUR3) promoter;'}{'i': 'Pichia pastoris', 'Pp03g05430 (ScTHI4) promoter;'}{'i': 'Pichia pastoris', 'Pp03g03490 (AN2957.2) promoter;'}{'i': 'Pichia pastoris', 'Pp05g09410 (ScTHI13) promoter;'}{'i': 'Pichia pastoris', 'Pp02g07970 (ScPEX11/PMP27) promoter;'}{'i': 'Pichia pastoris', 'Pp01g12200 (AN7917.2) promoter;'}{'i': 'Pichia pastoris', 'Pp03g11380 (ScPMP47) promoter;'}{'i': 'Pichia pastoris', 'Pp03g08340 promoter;'}{'i': 'Pichia pastoris', 'Pp05g04390 (ScTIR3) promoter;'}{'i': 'Pichia pastoris', 'Pp01g08380 (ScYIL057c) promoter;'}{'i': 'Pichia pastoris', 'Pp01g05090 (ScSAY1) promoter;'}{'i': 'Pichia pastoris', 'Pp01g13950 ( ...

BINDING PROTEINS AND ANTIGEN BINDING FRAGMENTS THEREOF THAT BIND ABETA

Binding proteins that bind amyloid beta (Abeta) are described, including heavy chain antibody variable domain (VHH) constructs comprising human-like VHH comprising three synthetically generated complementarity determining region (CDR) areas. Human-like VHHs identified using these libraries may be useful for the manufacture of therapeutics for treating diseases and disorders.

Dynamic random access memory device and manufacturing method thereof

A DRAM device and its manufacturing method are provided. The DRAM device includes an interlayer dielectric layer and capacitor units framed on a substrate. The interlayer dielectric layer has capacitor unit accommodating through holes and includes a first support layer, a composite dielectric layer, and a second support layer sequentially formed on the substrate. The composite dielectric layer includes at least one first insulating layer and second insulating layer alternately stacked. Each capacitor unit accommodating through hole forms a first opening in the second insulating layer and forms a second opening communicating with the first opening in the first insulating layer. The second opening is wider than the first opening. The capacitor units are formed in the capacitor unit accommodating through holes. The top of the capacitor unit is higher than the top surface of the interlayer dielectric layer and defines a recessed region.

Capacitor structure

Provided is a capacitor structure including a substrate, a cup-shaped lower electrode, a top supporting layer, a capacitor dielectric layer, and an upper electrode. The cup-shaped lower electrode is located on the substrate. The top supporting layer surrounds the upper portion of the cup-shaped lower electrode. The top supporting layer includes a high-k material. Surfaces of the cup-shaped lower electrode and the top supporting layer are covered by the capacitor dielectric layer. A surface of the capacitor dielectric layer is covered by the upper electrode.

CHIP BONDING APPARATUS

A chip bonding apparatus includes a chamber, a chip transportation device, a heating device and a ventilation device. The chip transportation device is used for transferring at least one chip onto a carrier within the chamber. The chip transportation device is used for transferring at least one chip onto a carrier within the chamber. The heating device is used for providing heat to the at least one chip and/or the carrier within the chamber. The ventilation device communicates gas to flow through the chamber to form a negative pressure environment therein. The negative pressure environment is provided when the chip transportation device transfers at least one chip onto the carrier within the chamber, and a positive pressure is applied onto the at least one chip when the heating device provides heat to the at least one chip and/or the carrier. 1. A chip bonding apparatus , comprising:a chamber;a chip transportation device used for transferring at least one chip onto a carrier within the chamber;a heating device used for providing heat to the at least one chip and/or the carrier within the chamber; anda ventilation device for forcing a gas to flow through the chamber,wherein a negative pressure environment is provided within the chamber when the chip transportation device transfers the at least one chip onto the carrier and the at least one chip in the negative pressure environment is free of positive pressure and the temperature of the at least one chip is kept at room temperature within the chamber, anda positive pressure is applied onto the at least one chip when the heating device provides heat to the at least one chip and/or the carrier.2. The chip bonding apparatus according to claim 1 , wherein the chip transportation device comprises a plurality of pickers capable of concurrently picking and transferring a plurality of chips onto the carrier.3. The chip bonding apparatus according to claim 2 , wherein the chip transportation device further comprises an ...

ENGINEERED PICHIA STRAINS WITH IMPROVED FERMENTATION YIELD AND N-GLYCOSYLATION QUALITY

The present invention relates to novel engineered strains with improved fermentation yields for expressing heterologous proteins with improved N-glycosylation quality, as well as to methods of generating such strains. 1Pichia. An isolated modified sp. host cell wherein the host cell has been modified to reduce or eliminate expression of a functional gene product of a nucleic acid sequence encoding a polypeptide having the amino acid sequence set forth in SEQ ID NO:76.2. The host cell of claim 1 , wherein said modified host cell comprises a disruption or deletion in the nucleic acid sequence encoding a polypeptide having the amino acid sequence set forth in SEQ ID NO:76.3. The host cell of claim 1 , which further comprises disruption or deletion of one or more of a functional gene products encoding an alpha-1 claim 1 ,6-mannosyltransferase activity claim 1 , mannosylphosphate transferase activity claim 1 , β-mannosyltransferase activity claim 1 , or a dolichol-P-Man dependent alpha(1-3) mannosyltransferaseactivity.4. The host cell of claim 1 , further comprising one or more nucleic acid sequences of interest.5. The host cell of claim 4 , wherein the nucleic acid sequences of interest encode one or more glycosylation enzymes or oligosaccharyltransferases.6. The host cell of claim 5 , wherein the glycosylation enzymes are selected from the group consisting of glycosidases claim 5 , mannosidases claim 5 , phosphomannosidases claim 5 , phosphatases claim 5 , nucleotide sugar transporters claim 5 , mannosyltransferases claim 5 , the N-acetylglucosaminyltransferases claim 5 , the UDP-N-acetylglucosamine transporters claim 5 , the galactosyltransferases claim 5 , the sialyltransferases claim 5 , the protein mannosyltransferases claim 5 , and the oligosaccharyltransferases STT3A claim 5 , STT3B claim 5 , STT3C and STT3D.7. The host cell of claim 6 , wherein the nucleic acid sequences of interest encode one or more therapeutic proteins.8. The host cell of claim 7 , wherein ...

DYNAMIC RANDOM ACCESS MEMORY DEVICE AND MANUFACTURING METHOD THEREOF

A DRAM device and its manufacturing method are provided. The DRAM device includes an interlayer dielectric layer and capacitor units framed on a substrate. The interlayer dielectric layer has capacitor unit accommodating through holes and includes a first support layer, a composite dielectric layer, and a second support layer sequentially formed on the substrate. The composite dielectric layer includes at least one first insulating layer and second insulating layer alternately stacked. Each capacitor unit accommodating through hole forms a first opening in the second insulating layer and forms a second opening communicating with the first opening in the first insulating layer. The second opening is wider than the first opening. The capacitor units are formed in the capacitor unit accommodating through holes. The top of the capacitor unit is higher than the top surface of the interlayer dielectric layer and defines a recessed region. 1. A dynamic random access memory (DRAM) device , comprising:a substrate; a first support layer formed on the substrate;', 'a composite dielectric layer formed on the first support layer, wherein the composite dielectric layer comprises at least one first insulating layer and at least one second insulating layer alternately stacked, wherein each of the capacitor unit accommodating through holes forms a first opening in the second insulating layer and forms a second opening communicating with the first opening in the first insulating layer, and wherein a width of the second opening is greater than a width of the first opening; and', 'a second support layer formed on the composite dielectric layer;, 'an interlayer dielectric layer formed on the substrate, wherein the interlayer dielectric layer has a plurality of capacitor unit accommodating through holes, and each of the capacitor unit accommodating through holes penetrates the interlayer dielectric layer, wherein the interlayer dielectric layer comprisesa plurality of capacitor units ...

PMT2-, OCH1-, PMT5- MUTANT CELLS

The presented invention relates to the gene knockouts of the PMT2 gene in the och1-glycoengineered strain backgrounds to obtain recombinant proteins reduced amounts of O-linked glycosylation. Triple mutant, pmt2, pmt5, och1 strains are also part of the present invention. Method for making such strains and for producing heterologous polypeptides in such strains are also included in the present invention. 1. An isolated fungal or lower eukaryotic host cell wherein said cell does not express functional PMT2 polypeptide , does not express functional OCH1 polypeptide; and , optionally , does not express functional PNT5 polypeptide.2Pichia. The isolated fungal or lower eukaryotic host cell of which is a cell.3. The isolated fungal or lower eukaryotic host cell of wherein endogenous PMT2 polynucleotide and/or endogenous OCH1 polynucleotide; and/or endogenous PMT5 polynucleotide is partially deleted claim 1 , fully deleted claim 1 , point mutated or disrupted.4. The isolated fungal or lower eukaryotic host cell of having a cell wall with an average N-glycan mannose content of about 3-10 mannose residues per N-glycan on said cell wall.5. The isolated fungal or lower eukaryotic host cell of which comprises a heterologous immunoglobulin polypeptide.6. A culture medium comprising the isolated fungal or lower eukaryotic host cell of .7Pichia pastoris. The isolated fungal or lower eukaryotic host cell of which is a cell.8. A method for producing an isolated pmt2- claim 1 , och1- or pmt2- claim 1 , och1- claim 1 , pmt5-fungal or lower eukaryotic host cell comprising expressing a site-specific recombinase in an och1- or och1- claim 1 , pmt5-fungal or lower eukaryotic host cell; wherein site-specific recombinase target sequences are at the 5′ and 3′ side of endogenous chromosomal PMT2 in the cell; and wherein claim 1 , the recombinase claim 1 , when expressed in the cell claim 1 , recombines the target sequences such that the PMT2 sequence between the target sequences is deleted ...

Affinity matured anti-lap antibodies and uses thereof

Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

High affinity antibodies targeting tau phosphorylated at serine 413

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

Vehicle bumper assembly

ABSTRACT A bumper assembly (1) for a vehicle comprises an impact member, preferably in the form of an elongate section (2) extending transversely of the fore and aft axis of an asso-ciated vehicle, and a plurality of buffer means, preferably in the form of resiliently deformable tubes (19), wherein the member (2) is movable upon impact to engage successively one or more of the plurality of buffer means (19) in depend-ence upon the force of such impact. In the preferred embodi-ment, the elongate section (2) comprises two arcuate portions arranged to engage successively respective resiliently deform-able tubes (19), with the section (2) being resiliently mounted upon the vehicle, for actuating switch means (S) for actuating an audible and/or visual indicator that at least an initial impact has occurred.

Work bench with clamping device

A work bench with a clamping device having several displaceable stops which can be displaced in U-rails by screw spindles and at the same time can be pivoted about horizontal and/or vertical axes and locked in position. The displaceable stops are rotatable about perpendicular axes. Two displaceable stops are preferably provided which act against one another, and one fixed stop acts against a further displaceable stop. In the case of a triangular work bench, three clamping devices arranged at the corners can also be arranged in a pivotable and lockable manner.

Human-like heavy chain antibody variable domain (vhh) display libraries

Heavy chain antibody variable domain (V H H) display libraries are described comprising human-like V H H comprising three synthetically generated complementarity determining region (CDR) areas in which the amino acids at each of positions 44 and 45 or positions 37, 44, 45, and 47comprise the amino acid at the corresponding position of a Camelid V H H, wherein the amino acid positions are according to Kabat numbering. Human-like V H Hs identified using these libraries may be useful for the manufacture of therapeutics for treating diseases and disorders.

Generative modeling leveraging deep learning for antibody affinity tuning

A computer-implemented method is disclosed for candidate antibody exploration. The method includes receiving sequence reads from a sequencing system, wherein each sequence read comprises a target gene for expressing a candidate antibody, wherein each sequence read is associated with a binding affinity to a target antigen. The method includes generating a sequence representation for each sequence read, representing the amino acid sequences of the sequence read. The method includes training a binding affinity prediction model with the sequence representations and the binding affinities. The method includes generating a synthetic candidate sequence read that is different from the sequence reads. The method includes generating a sequence representation for the synthetic candidate sequence read. The method includes determining a binging affinity prediction for the synthetic candidate sequence read by applying the binding affinity prediction model to the sequence representation for the synthetic candidate sequence read.

Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.

En el presente documento se proporcionan anticuerpos de alta afinidad o fragmentos de unión a antígeno de los mismos que se unen específicamente a tau-pS413 humana. También se proporcionan composiciones, kits, métodos y usos en los que están implicados tales anticuerpos o fragmentos de unión a antígeno de los mismos.

Dispositivo paraurti per veicoli

Automatic water quality monitoring buoy

Anticuerpos de alta afinidad dirigidos a tau fosforilados en la serina 413

En el presente documento se proporcionan anticuerpos de alta afinidad o fragmentos de unión a antígeno de los mismos que se unen específicamente a tau-pS413 humana. También se proporcionan composiciones, kits, métodos y usos en los que están implicados tales anticuerpos o fragmentos de unión a antígeno de los mismos.

Anticuerpos de alta afinidad dirigidos a tau fosforilada en serina 413.

En el presente documento se proporcionan anticuerpos de alta afinidad o fragmentos de unión a antígeno de los mismos que se unen específicamente a tau-pS413 humana. También se proporcionan composiciones, kits, métodos y usos en los que están implicados tales anticuerpos o fragmentos de unión a antígeno de los mismos.

Anti-blocking device for the deep water-pumping pipes

Conjunto de para-choques para veiculo automovel

Annular rotating roaster

This invention relates to an annular rotating roaster. The user may apply a cone-shaped flame separator which has numerous outstanding scales on its inner wall, when making a fire in the roaster. Each of the scales has a perforation beneath. The heat from the burning charcoal goes through the perforations and the scales to the meat. Thus, the meat won't be scorched. In addition, the degree of heat exposure is adjusted by the turning handle. Therefore, tender meat is produced. Moreover, the fat from the hot meat does not drop directly on the burning charcoal. As a result, no smoke or ashes rise, keeping the meat from being contaminated.

Engineered pichia strains with improved fermentation yield and n-glycosylation quality

The present invention relates to novel engineered Pichia strains with improved fermentation yields for expressing heterologous proteins with improved N-glycosylation quality, as well as to methods of generating such strains.

Engineered pichia strains with improved fermentation yield and n-glycosylation quality

The present invention relates to novel engineered Pichia strains with improved fermentation yields for expressing heterologous proteins with improved N-glycosylation quality, as well as to methods of generating such strains.

Trop2 binders and conjugates thereof

TROP2 binders and variants thereof are described. In a specific embodiment, the TROP2 binders that are antibodies that preferentially bind high-expressing TROP2 cells over low-expressing TROP2 cells and conjugates thereof comprising the TROP2 binders conjugated to a payload are described.

Trop2 binders and conjugates thereof

TROP2 binders and variants thereof are described. In a specific embodiment, the TROP2 binders that are antibodies that preferentially bind high-expressing TROP2 cells over low-expressing TROP2 cells and conjugates thereof comprising the TROP2 binders conjugated to a payload are described.

Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives

Anti-TROP2 antibody-drug conjugates comprising derivatives of the anthracycline metabolite PNU-159682 conjugated to an antibody that preferentially binds high-expressing TROP2 cells over low-expressing TROP2 cells are disclosed.